ANN ARBOR, MI / ACCESSWIRE / March 8, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Wednesday, March 15, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its fourth quarter and fiscal year ended December 31, 2022. A question-and-answer session will follow management's prepared remarks.
| Event: | Zomedica Q4 and Fiscal Year 2022 Financial Results Conference Call |
| Date: | Wednesday, March 15, 2023 |
| Time: | 4:30 p.m. Eastern Time |
| Live Call: | +1-877-407-0789 (U.S. Toll-Free) or +1-201-689-8562 (International) |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1601606&tp_key=1c4e47625b |
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until March 29, 2023 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13736703.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Email Alerts: http://investors.zomedica.com
LinkedIn: https://www.linkedin.com/company/zomedica
Facebook: https://m.facebook.com/zomedica
Twitter: https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Investor Relations Contact:
RedChip Companies Inc.
Barrett Boone
barrett@redchip.com
407-571-0912
| Last Trade: | US$0.05 |
| Daily Change: | -0.01 -16.67 |
| Daily Volume: | 229,335 |
February 06, 2025 December 23, 2024 November 27, 2024 November 14, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
